^
Association details:
| Biomarker: | SMO D477G |
|---|---|
| Cancer: | Medulloblastoma |
| Drug: | itraconazole (CYP51A1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
Excerpt:
Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMO(D477G) medulloblastoma.
Secondary therapy:
arsenic trioxide
DOI:
10.1016/j.ccr.2012.11.017
Source:
Title:
Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists
Excerpt:
Itraconazole and arsenic trioxide, alone or in combination, inhibit the growth of medulloblastoma and basal cell carcinoma in vivo, and prolong survival of mice with intracranial drug-resistant SMO(D477G) medulloblastoma.
DOI:
10.1016/j.ccr.2012.11.017
